Sun et al. demonstrated that CD133+CXCR4+ primary endometrial cancer cells grew faster, exhibited high expression of stemness-related genes, produced more spheres, had higher clonogenic ability, and more resistant to anti-cancer drugs than other subpopulations, indicating that CD133+CXCR4+ cells may possess some characteristics of CSCs in primary endometrial cancer (29). The gene discussed is PROM1; the disease is cancer.